A Prospective Observational Study of Antihemophilic Factor (Recombinant) Prophylaxis Related to Physical Activity Levels in Patients with Hemophilia A in the United States (SPACE)

Barbara A Konkle,1 Doris V Quon,2 Leslie Raffini,3 Michael Recht,4 Vlad C Radulescu,5 Shannon L Carpenter,6 Amy L Dunn,7 Mei Lu,8 Maureen Watt9 1Department of Medicine, The University of Washington and Bloodworks Northwest, Seattle, WA, USA; 2Orthopaedic Hemophilia Treatment Center, Orthopaedic Institute for Children, Los Angeles, CA, USA; 3Division of Hematology, Children’s Hospital of Philadelphia, Philadelphia, PA, USA; 4The Hemophilia Center, Oregon Health & Science University, Portland, OR, USA; 5Department of Pediatric Hematology and Oncology, University of Kentucky Medical Center, Lexington, KY, USA; 6Department of Hematology/Oncology, Children’s Mercy Hospital, Kansas City, MO, USA; 7Hemophilia Treatment Center, Nationwide Children’s Hospital and The Ohio State University College of Medicine, Columbus, OH, USA; 8Takeda Development Center Americas, Inc, Lexington, MA, USA; 9Outcomes Research & Epidemiology, Takeda Pharmaceuticals International AG, Zurich, SwitzerlandCorrespondence: Maureen WattTakeda Pharmaceuticals International AG, Thurgauerstrasse 130, Glattpark-Opfikon, Zurich, 8152, SwitzerlandTel +41 44 555 10 00Fax +41 44 555 10 01Email maureen.watt@takeda.comIntroduction: High collision-risk physical activity can increase bleeding risk in people with hemophilia A, as can increasing the time between factor VIII (FVIII) administration and physical activity. FVIII prophylaxis may be tailored to planned activities to prevent activity-related bleeding.Aim: To explore the relationship between physical activity levels, FVIII infusion timing, and occurrence of bleeding in patients with severe/moderately severe hemophilia A without FVIII inhibitors receiving antihemophilic factor (recombinant) (rAHF; ADVATE®; Baxalta US Inc., a Takeda company, Lexington, MA, USA).Methods: SPACE was a 6-month, prospective, multicenter, observational outcomes study (NCT02190149). Enrolled patients received an eDiary application and a wearable activity tracker, whi